Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 +3.03%64 EV-to-EBITDA is 10.16 as of Aug. 24, 2026, which is 30% below its 10-year median of 14.61. GuruFocus rates TSE:4512 with a GF Score™ of 64/100 and a GF Value™ of 円309.66 (Fairly Valued). The stock has 3 warning signs investors should review. Among 739 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks better than 60.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wakamoto Pharmaceutical Co's enterprise value is 円8,790 Mil.
Wakamoto Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円865 Mil. Therefore, Wakamoto Pharmaceutical Co's EV-to-EBITDA for today is 10.16.
The historical rank and industry rank for Wakamoto Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TSE:4512'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2975.17 Med: 14.61 Max: 152.49
Current: 10.16
During the past 13 years, the highest EV-to-EBITDA of Wakamoto Pharmaceutical Co was 152.49. The lowest was -2975.17. And the median was 14.61.
TSE:4512's EV-to-EBITDA is ranked better than 60.08% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.2
vs TSE:4512: 10.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Wakamoto Pharmaceutical Co (TSE:4512) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wakamoto Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Wakamoto Pharmaceutical Co's share price for today is 円306.00.
Wakamoto Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's EV-to-EBITDA falls into.
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,790 Mil.
Wakamoto Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円865 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a EV-to-EBITDA of 10.16 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wakamoto Pharmaceutical Co. This is 30% below median its historical median of 14.61. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #295 out of 739 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Wakamoto Pharmaceutical Co's EV-to-EBITDA too high?
Wakamoto Pharmaceutical Co's current EV-to-EBITDA of 10.16 is 30% below median its 10-year median of 14.61. The Drug Manufacturers industry median EV-to-EBITDA is 13.20. Wakamoto Pharmaceutical Co's value of 10.16 is 23% below this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #295 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #295 out of 739 companies for EV-to-EBITDA. This puts Wakamoto Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.20. Wakamoto Pharmaceutical Co's value of 10.16 is 23% below this benchmark. While the company's 10-year median is 14.61 vs. the industry median of 13.20, Wakamoto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.20, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current EV-to-EBITDA of 10.16 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wakamoto Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current EV-to-EBITDA is 10.16, which is 30% below median its own 10-year median of 14.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円309.66, compared to a current price of 円306.00 — trading 1.2% below its estimated fair value. The current EV-to-EBITDA is 10.16, which is 30% below median its 10-year median of 14.61 and 23% below the Drug Manufacturers industry median of 13.20. Wakamoto Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current EV-to-EBITDA is 10.16 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円306.00 is trading 1.2% below its estimated GF Value™ of 円309.66.
GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4512:
EV-to-EBITDA: 10.16 (30% below median its 10-year median of 14.61)
GF Value™: 円309.66 vs. price of 円306.00 (1.2% below fair value)
Industry Position: 23% below the Drug Manufacturers median (#295 of 739)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
64GF Score
Get the complete analysis for TSE:4512
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
